Drug
N1539
N1539: highest development phase Phase 2, developed by Alkermes. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alkermes
Trials
| Drug | Phase | Indication |
|---|---|---|
| N1539 NCT01084161 | Phase 2 | Hysterectomy |
| N1539 NCT00945763 | Phase 2 | Dental Pain |
Latest
No recent events.
Follow N1539 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.